Compare Mesoblast Limited (MESO) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Williams-Sonoma, Inc. — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while Williams-Sonoma, Inc. trades at $241.78 (market cap $28.15B). The key difference: Williams-Sonoma, Inc. is far larger — about 16.1× Mesoblast Limited's market cap, and Williams-Sonoma, Inc. pays a 1.27% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Williams-Sonoma, Inc. for 59 Days on average.
| MESO | WSM | |
|---|---|---|
Market Cap | $1.75B | $28.15B |
Volume | 239,027 | 1,351,262 |
Sector | Health | Consumer Cyclical |
52-Week High | $20.96 | $251.81 |
52-Week Low | $13.19 | $168.64 |
Typical Hold Time | 15 Days | 59 Days |
Enterprise Value | $1.83B | $28.65B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
Williams-Sonoma (WSM) trades at $239.00, down 0.61% on the day, with a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.10 surpassing expectations. Profitability remains robust, with a net income margin of 14.73% and ROE of 54.96%. Recent news highlights market share gains and AI integration driving growth.
The outlook is positive, supported by raised full-year guidance and strong operational execution. Key opportunities include margin expansion and dividend growth, while risks involve housing market sensitivity and competitive pressures. Analyst consensus leans bullish with a $246.31 price target, suggesting modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
